Filing Flows

Filing Flows › Health Care › Coya Therapeutics (COYA)

Coya Therapeutics (COYA) earnings and revenue breakdown

Latest: Q2 2026 · 10-Q filed Aug 11, 2026 · Coya Therapeutics (COYA) Q2 2026 earnings results →

Q2 2026 Revenue up 49% year over year to $244K

Coya Therapeutics made $244K in Q2 2026 (+49% Y/Y). Operating margin n/m, net loss $6.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2026.

Revenue$244K
Year over year+49%
Operating marginn/m
Net earnings−$6.6M
Operating cash flow−$7.4M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $244K in Q2 2026, up 49% year over year and down 3% from the previous quarter.

Operating costs exceeded revenue by $7.0M, an operating margin of -2891.1%. Total costs grew 11% against revenue growth of 49%. The fastest-growing cost line was Research & development (+37%). The quarter ended with a net loss of $6.6M, narrower than the previous quarter's $7.2M loss.

Operating cash flow was −$7.4M. Non-cash charges added back $3K of depreciation and $944K of share-based compensation. Working capital and other items used $1.7M.

Quarterly history

Coya Therapeutics revenue by quarterCoya Therapeutics revenue by quarter$2KQ4 2024$258KQ1 2025$164KQ2 2025$3.6MQ3 2025$4.0MQ4 2025$251KQ1 2026$244KQ2 2026
Coya Therapeutics net earnings by quarterCoya Therapeutics net earnings by quarter−$2.9MQ4 2024−$7.3MQ1 2025−$6.1MQ2 2025−$2.1MQ3 2025−$5.7MQ4 2025−$7.2MQ1 2026−$6.6MQ2 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q2 202610-QAug 11, 2026$244K+49%n/m−$6.6M−$7.4M
Q1 202610-QMay 12, 2026$251K-3%n/m−$7.2M−$6.2M
Q4 202510-KMar 16, 2026$4.0M2,029×-152.3%−$5.7M−$1.0M
Q3 202510-QNov 12, 2025$3.6M—-68.3%−$2.1M−$1.1M
Q2 202510-QAug 12, 2025$164K-95%n/m−$6.1M−$5.8M
Q1 202510-QMay 13, 2025$258K+103%n/m−$7.3M−$2.8M
Q4 202410-KMar 18, 2025$2K-100%n/m−$2.9M−$2.4M

Charts

Coya Therapeutics: revenue growth, year over year and quarter over quarterCoya Therapeutics: revenue growth, year over year and quarter over quarterY/YQ/Q-100%Q4 2024+103%+400%Q1 2025-95%-37%Q2 2025+400%Q3 2025+400%+11%Q4 2025-3%-94%Q1 2026+49%-3%Q2 2026
Latest (Q2 2026): Y/Y +49%, Q/Q -3%.
Coya Therapeutics: where the cash came from (+) and went (−), TTM to Q2 2026Coya Therapeutics: where the cash came from (+) and went (−), TTM to Q2 2026Other financing$31.2MOperating cash flow−$15.7MCash drawn (+) / kept (−)−$13.4MNot reconciled−$2.1M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Coya Therapeutics: profit against cash, quarter by quarterCoya Therapeutics: profit against cash, quarter by quarterNet incomeOperating cash flow−$4.0M−$5.5MQ3 2024−$2.9M−$2.4MQ4 2024−$7.3M−$2.8MQ1 2025−$6.1M−$5.8MQ2 2025−$2.1M−$1.1MQ3 2025−$5.7M−$1.0MQ4 2025−$7.2M−$6.2MQ1 2026−$6.6M−$7.4MQ2 2026
Latest (Q2 2026): Net income −$6.6M, Operating cash flow −$7.4M.
Coya Therapeutics: diluted shares by fiscal year (split-adjusted)Coya Therapeutics: diluted shares by fiscal year (split-adjusted)10MFY202110MFY202210MFY202315MFY202417MFY2025
+61.5% since FY2021: more shares outstanding (issuance, stock pay); earlier years scaled for the 4-for-1 split before FY2023.
Coya Therapeutics in its industry: growth against margin (225 companies, SIC 2834)Coya Therapeutics in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLSCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMCOYA (+49%, -100%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Coya Therapeutics

All references in this report to "Coya," the "Company," "we," "us," or "our" mean Coya Therapeutics, Inc. unless stated otherwise or the context otherwise indicates. We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (“Tregs”). Tregs are a subpopulation of T-lymphocytes consisting of CD4+CD25high hFOXP3+ cells that suppress inflammatory responses. Tregs were first discovered in 1995 by Dr. Shimon Sakaguchi and since their discovery multiple lines of research have contributed to elucidate Treg biology and its role in health and disease. Dr. Sakaguchi was the 2025 winner of the Nobel Prize in Physiology or Medicine.

In its own words, from its 10-K, filed Mar 16, 2026.

Coya Therapeutics against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +49% against the peers' median +10%.

CompanyQuarterRevenueY/YOp. margin
COYA Coya TherapeuticsQ2 2026$244K+49%n/m
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Coya Therapeutics 10-Q on SEC EDGAR · CIK 1835022 · Pharmaceutical Preparations

13F: who owns COYA and who is buying

Largest holders of COYA (13F)Largest holders of COYA (13F)DME Capital Management, LP$13.7MVanguard Group$5.2MVanguard Capital Management LLC$4.9MAlyeska Investment Group, L.P.$4.7MAigh Capital Management LLC$3.2MPrivate Management Group$1.9MMarshall Wace, LLP$1.5MGeode Capital Management, LLC$1.3MRenaissance Technologies LLC$1.1MProsight Management, LP$994K
Funds' net buying of COYA by quarter (13F)Funds' net buying of COYA by quarter (13F)−$64K2024-09−$6.0M2024-12$69K2025-03−$277K2025-06$290K2025-09$2.4M2025-12$3.0M2026-03−$2.0M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on COYA

History

Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results

Compare COYA with

中文版：Coya Therapeutics（COYA）财报

Español · Français